Cytosorbents (CTSO) EBT Margin Growth (5y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -469.00 |
| Dec 31, 2025 | -5,536.00 |
| Sep 30, 2025 | -2,969.00 |
| Jun 30, 2025 | -1,473.00 |
| Mar 31, 2025 | 2,271.00 |
| Dec 31, 2024 | -3,331.00 |
| Sep 30, 2024 | 8,082.00 |
| Jun 30, 2024 | 1,006.00 |
| Mar 31, 2024 | 2,634.00 |
| Dec 31, 2023 | 26,661.00 |
| Sep 30, 2023 | -5,202.00 |
| Jun 30, 2023 | 3,583.00 |
| Mar 31, 2023 | -1,697.00 |
| Dec 31, 2022 | 6,250.00 |
| Sep 30, 2022 | -9,670.00 |
| Jun 30, 2022 | -7,942.00 |
| Mar 31, 2022 | -5,419.00 |
| Dec 31, 2021 | 7,629.00 |
| Sep 30, 2021 | 2,509.00 |
| Jun 30, 2021 | 9,633.00 |
| Mar 31, 2021 | 6,212.00 |
| Dec 31, 2020 | 19,340.00 |
| Sep 30, 2020 | 20,396.00 |
| Jun 30, 2020 | -17,807.00 |
| Mar 31, 2020 | 61,269.00 |
| Dec 31, 2019 | 54,798.00 |
| Sep 30, 2019 | 1,594.00 |
| Jun 30, 2019 | 12,398.00 |
| Mar 31, 2019 | -227.00 |
| Dec 31, 2018 | -4,018.00 |
| Sep 30, 2018 | 9,016.00 |
| Jun 30, 2018 | 100,459.00 |
| Mar 31, 2018 | 86,447.00 |
| Dec 31, 2017 | 97,430.00 |
| Sep 30, 2017 | 471,257.00 |
| Jun 30, 2017 | 204,598.00 |
| Mar 31, 2017 | 279,138.00 |
| Dec 31, 2016 | 314,826.00 |